1783 Stock Overview
Researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for 1783 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Maxigen Biotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$46.90 |
| 52 Week High | NT$51.50 |
| 52 Week Low | NT$37.25 |
| Beta | 0.89 |
| 1 Month Change | 6.59% |
| 3 Month Change | 11.27% |
| 1 Year Change | -2.19% |
| 3 Year Change | 6.42% |
| 5 Year Change | 117.55% |
| Change since IPO | 7.69% |
Recent News & Updates
Recent updates
Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft Earnings
Nov 20
Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable Quality
Mar 28Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?
Apr 22We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) Earnings
Apr 01Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Mar 16The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For More
Feb 23Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?
Feb 02Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend Yield
Jan 10Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?
Dec 14If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%
Nov 22
Shareholder Returns
| 1783 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -2.1% | -2.6% | -2.1% |
| 1Y | -2.2% | -0.8% | 25.6% |
Return vs Industry: 1783 underperformed the TW Biotechs industry which returned -0.8% over the past year.
Return vs Market: 1783 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 1783 volatility | |
|---|---|
| 1783 Average Weekly Movement | 3.1% |
| Biotechs Industry Average Movement | 4.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1783 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1783's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Ching-Ting Chen | mbi-bio.com |
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; and BestAid, a collagen bone graft.
Maxigen Biotech Inc. Fundamentals Summary
| 1783 fundamental statistics | |
|---|---|
| Market cap | NT$4.18b |
| Earnings (TTM) | NT$155.34m |
| Revenue (TTM) | NT$623.76m |
26.9x
P/E Ratio6.7x
P/S RatioIs 1783 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1783 income statement (TTM) | |
|---|---|
| Revenue | NT$623.76m |
| Cost of Revenue | NT$188.87m |
| Gross Profit | NT$434.88m |
| Other Expenses | NT$279.55m |
| Earnings | NT$155.34m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.74 |
| Gross Margin | 69.72% |
| Net Profit Margin | 24.90% |
| Debt/Equity Ratio | 0% |
How did 1783 perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield57%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maxigen Biotech Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Regina Lee | Capital Securities Corporation |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |
| Hsiu Chi Lin | Masterlink Securities Corp. |